Photocure Valuation
Is PHCU.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PHCU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PHCU.F ($4.48) is trading below our estimate of fair value ($32.93)
Significantly Below Fair Value: PHCU.F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHCU.F?
Key metric: As PHCU.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PHCU.F's PE Ratio? | |
|---|---|
| PE Ratio | 94.2x |
| Earnings | NOK 14.16m |
| Market Cap | NOK 1.34b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 18.2x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does PHCU.F's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.8x | ||
PROC Procaps Group | 3.3x | n/a | US$170.4m |
BTMD biote | 28.6x | 64.8% | US$240.5m |
SIGA SIGA Technologies | 6.1x | n/a | US$519.8m |
ORMP Oramed Pharmaceuticals | 21.4x | -163.0% | US$95.5m |
PHCU.F Photocure | 94.2x | 94.9% | US$1.3b |
Price-To-Earnings vs Peers: PHCU.F is expensive based on its Price-To-Earnings Ratio (94.2x) compared to the peer average (15.2x).
Price to Earnings Ratio vs Industry
How does PHCU.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Earnings vs Industry: PHCU.F is expensive based on its Price-To-Earnings Ratio (94.2x) compared to the US Pharmaceuticals industry average (19.8x).
Price to Earnings Ratio vs Fair Ratio
What is PHCU.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 94.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHCU.F's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | US$7.63 0% | 0.6% | US$7.67 | US$7.58 | n/a | 2 |
| Nov ’25 | n/a | US$7.82 0% | 1.2% | US$7.91 | US$7.73 | n/a | 2 |
| Oct ’25 | n/a | US$8.02 0% | 1.2% | US$8.12 | US$7.93 | n/a | 2 |
| Sep ’25 | n/a | US$8.02 0% | 1.2% | US$8.12 | US$7.93 | n/a | 2 |
| Aug ’25 | n/a | US$7.95 0% | 1.2% | US$8.04 | US$7.85 | n/a | 2 |
| Jul ’25 | US$5.12 | US$8.06 +57.5% | 1.2% | US$8.16 | US$7.97 | n/a | 2 |
| Jun ’25 | n/a | US$8.06 0% | 1.2% | US$8.16 | US$7.97 | n/a | 2 |
| May ’25 | n/a | US$8.16 0% | 1.2% | US$8.26 | US$8.07 | n/a | 2 |
| Apr ’25 | n/a | US$8.16 0% | 1.2% | US$8.26 | US$8.07 | n/a | 2 |
| Mar ’25 | US$5.95 | US$8.16 +37.2% | 1.2% | US$8.26 | US$8.07 | n/a | 2 |
| Feb ’25 | n/a | US$8.80 0% | 2.7% | US$9.03 | US$8.56 | n/a | 2 |
| Jan ’25 | US$6.10 | US$8.33 +36.5% | 2.7% | US$8.55 | US$8.10 | n/a | 2 |
| Dec ’24 | n/a | US$8.33 0% | 2.7% | US$8.55 | US$8.10 | n/a | 2 |
| Nov ’24 | n/a | US$8.49 0% | 5.3% | US$8.94 | US$8.04 | n/a | 2 |
| Oct ’24 | US$5.00 | US$8.59 +71.8% | 11.1% | US$9.54 | US$7.64 | n/a | 2 |
| Sep ’24 | n/a | US$8.59 0% | 11.1% | US$9.54 | US$7.64 | n/a | 2 |
| Aug ’24 | n/a | US$9.87 0% | 10.0% | US$10.85 | US$8.88 | n/a | 2 |
| Jul ’24 | n/a | US$9.59 0% | 12.2% | US$10.76 | US$8.42 | US$5.12 | 2 |
| Jun ’24 | n/a | US$9.59 0% | 12.2% | US$10.76 | US$8.42 | n/a | 2 |
| May ’24 | n/a | US$9.59 0% | 12.2% | US$10.76 | US$8.42 | n/a | 2 |
| Apr ’24 | n/a | US$10.07 0% | 14.3% | US$11.51 | US$8.63 | n/a | 2 |
| Mar ’24 | US$7.90 | US$10.11 +28.0% | 14.3% | US$11.56 | US$8.67 | US$5.95 | 2 |
| Feb ’24 | n/a | US$12.23 0% | 12.0% | US$13.70 | US$10.76 | n/a | 2 |
| Jan ’24 | n/a | US$12.23 0% | 12.0% | US$13.70 | US$10.76 | US$6.10 | 2 |
| Dec ’23 | n/a | US$12.23 0% | 12.0% | US$13.70 | US$10.76 | n/a | 2 |
| Nov ’23 | n/a | US$12.24 0% | 7.7% | US$13.19 | US$11.30 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
BeiGene
US$21.9b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
BGNE
US$206.16
7D
8.2%
1Y
10.0%
Collegium Pharmaceutical
US$990.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.71
7D
2.5%
1Y
20.0%
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$201.43
7D
-0.2%
1Y
-7.1%